EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Pragmatische StudieOpen Access · CC BY 4.0

Plasma Lipidomic Features of Adolescent Major Depressive Disorder and Lipid Changes After Fluoxetine Treatment

Chenxi Liu iD, Yao Li iD, Hanchen Hou, Jiamei Guo, Bingjie Qin, Xiaoxia Xu iD, Yuqian He, Tingting Lei, Fei Chen iD, Lige Zhang iD, Quanbing Liu, Li Gao und 5 weitere

CNS Neuroscience & Therapeutics · 2026-11 · 32 (11)

DOI: 10.1002/cns.71202 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 29.10.2026. Verfasst von Chenxi Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Key Laboratory of Major Brain Disease and Aging Research (Ministry of Education), The First Affiliated Hospital of Chongqin…. Hauptthemen laut MEDLINE: Antidepressive Agents, Second-Generation, Fluoxetine, Lipid Metabolism, Lipidomics. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: STI2030-Major Projects, National Key R&D Program of China, the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Major depressive disorder (MDD) in adolescents is a major public health concern, yet objective biological markers and treatment‐related metabolic changes remain insufficiently understood. This study aimed to characterize plasma lipidomic alterations in adolescent MDD and explore lipid changes associated with fluoxetine treatment.

Methods

This study enrolled 75 adolescents with MDD and 75 matched healthy controls (HCs). Among the adolescents with MDD, 44 had paired baseline and week‐8 plasma samples available and were included in the longitudinal analysis. Plasma lipidomic profiles were analyzed using ultra‐high‐performance liquid chromatography–tandem mass spectrometry (UHPLC–MS/MS).

Results

A total of 865 lipid species were detected. Compared with HCs, adolescents with MDD showed distinct plasma lipidomic profiles, with 82 differentially abundant lipid species identified, primarily involving triglycerides, lysophospholipids, free fatty acids, membrane phospholipids, and sphingolipids. Among the machine‐learning models, logistic regression showed the highest discriminative performance, with a pooled out‐of‐fold AUC of 0.85 (95% CI, 0.79–0.91). Longitudinal analysis identified 21 lipid species meeting the differential criteria following fluoxetine treatment, mainly involving triglycerides and bile acid‐related metabolites. Integrative pathway and target analyses suggested that fluoxetine‐associated lipid changes may involve neurotransmitter signaling, inflammatory lipid metabolism, PI3K–Akt signaling, and nuclear receptor‐related pathways.

Conclusion

This study characterizes alterations in plasma lipid metabolism in adolescent MDD and the lipidomic changes following fluoxetine treatment, providing new lipidomic evidence for candidate lipid signatures and potential treatment‐associated biological pathways. Trial Registration ClinicalTrials.gov , NCT05814640. Registered 20 February 2023, https://clinicaltrials.gov/study/NCT05814640

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidepressive Agents, Second-GenerationFluoxetineLipid MetabolismLipidomicsLipidsMajor Depressive DisorderSelective Serotonin Reuptake InhibitorsAdolescentFemaleHumansMaleChromatography, High Pressure LiquidLongitudinal Studies

Stichwörter der Autor:innen

Major depressive disorderadolescentfluoxetinelipidomics

Substanzen

Antidepressive Agents, Second-GenerationFluoxetineLipidsSelective Serotonin Reuptake Inhibitors

Autor:innen und Institutionen

  • Department of Psychiatry, Key Laboratory of Major Brain Disease and Aging Research (Ministry of Education), The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

ORCID-Profile: Chenxi Liu, Yao Li, Xiaoxia Xu, Fei Chen, Lige Zhang, Xinyu Zhou

Förderung

  • STI2030-Major Projects
  • National Key R&D Program of China
  • the National Natural Science Foundation of China
  • New Chongqing Youth Innovation Talent Project
  • Chongqing Medical Scientific Research Project: Joint Project of Chongqing Health Commission and Science and Technology Bureau
  • National Key Research and Development Program of China

Zitieren

APA

Liu, C., Li, Y., Hou, H., Guo, J., Qin, B., Xu, X., He, Y., Lei, T., Chen, F., Zhang, L., Liu, Q., Gao, L., Shi, J., Xing, H., Teng, T., Qiu, T., & Zhou, X. (2026). Plasma Lipidomic Features of Adolescent Major Depressive Disorder and Lipid Changes After Fluoxetine Treatment. CNS Neuroscience & Therapeutics, 32(11). https://doi.org/10.1002/cns.71202

Vancouver

Liu C, Li Y, Hou H, Guo J, Qin B, Xu X, et al. Plasma Lipidomic Features of Adolescent Major Depressive Disorder and Lipid Changes After Fluoxetine Treatment. CNS Neuroscience & Therapeutics. 2026;32(11). doi:10.1002/cns.71202

BibTeX
@article{Liu2026,
  author = {Liu, Chenxi and Li, Yao and Hou, Hanchen and Guo, Jiamei and Qin, Bingjie and Xu, Xiaoxia and He, Yuqian and Lei, Tingting and Chen, Fei and Zhang, Lige and Liu, Quanbing and Gao, Li and Shi, Jiaqi and Xing, Haoran and Teng, Teng and Qiu, Tian and Zhou, Xinyu},
  title = {Plasma Lipidomic Features of Adolescent Major Depressive Disorder and Lipid Changes After Fluoxetine Treatment},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2026},
  volume = {32},
  number = {11},
  doi = {10.1002/cns.71202}
}
Kostenlos starten →